Introduction
Systemic fibrosis is a feature of autoimmune disease such as systemic sclerosis (SSc) or Sjö gren's syndrome involving exocrine glands (Ferrara et al., 2009; Filipovich et al., 2005) . A mouse model for human SSc reported by Zhang et. al. involves transplantation of B10.D2 bone marrow into MHC matched, minor antigen mismatched BALB/c host (Zhang et al., 2002) . This model of SSc occurs spontaneously without the use of artificial agents such as bleomycin (Yamamoto and Nishioka, 2004) , and exhibits characteristics of human SSc including fibrosis, inflammation, and autoimmunity. Animal models are effective in screening for therapeutic interventions such as anti IL-6 (Le Huu et al., 2012) and angiotensin II type-1 receptor antagonists (Yaguchi et al., 2013) . However, such a spontaneous model is also a valuable tool for investigating the pathogenesis of SSc, which is still largely unknown.
In order to shed light onto the mechanisms leading to fibrosis in this SSc mouse model, it is necessary to isolate the different cellular fractions within the B10.D2 donor bone marrow, namely, hematopoietic stem cells (HSCs) and bone marrow stromal/stem cells (BMSCs). Multipotent BMSCs in the bone marrow differentiate into several mesenchymal lineages including fibroblasts, adipocytes, osteocytes, and chondrocytes (Pittenger et al., 1999; Prockop, 1997) . However, due to the lack of specific markers, a crucial step involving in vitro expansion was required to isolate BMSCs, which may modify their phenotype and function (Banfi et al., 2000) . Most current information on BMSCs comes from such in vitro studies of adherent cells referred to as fibroblast CFUs (CFU-Fs) (Conget and Minguell, 1999; Friedenstein et al., 1974; Pittenger et al., 1999; Prockop, 1997) , which are a heterogeneous population of cells at best. Therefore, the in vivo dynamics of BMSCs after whole bone marrow transplantation (WBMT) are still unknown, and the establishment of a solid experimental system to trace the fate of BMSCs following transplantation was required.
In order to establish an animal model with traceable donor BMSCs and HSCs, we applied our previously reported method for prospectively isolating murine BMSCs based on their expression of PDGF receptor a and Sca-1 (PDGFRa + / Sca-1 + (PaS) cells) (Morikawa et al., 2009a) . Selectively isolated PaS-BMSCs without in vitro expansion represents highly clonogenic and multi-potent population of cells including hematopoietic niche cells, osteoblasts, and adipocytes after systemic in vivo transplantation (Morikawa et al., 2009a; 2009b) . Our model allows for the first time both whole bone marrow transplantation, as well as the selective transplantation of freshly isolated BMSCs and/ or HSCs into recipient mice. By applying this modified SSc model using prospectively isolated BMSCs and HSCs, we sought to identify the role of donor HSCs and BMSCs in the pathogenesis of the autoimmune-related fibrosis in SSc. Here, we show how mismatched donor BMSCs not only contribute to fibrosis in various organs, but also trigger the onset of autoimmune disease by activating host T cells.
eLife digest Systemic scleroderma is an autoimmune disease caused by the immune system attacking the body's connective tissues, which provide the body with structural support. Immune cells called T cells accumulate in connective tissue, which leads to the hardening of the skin and may also damage the heart, lungs and other internal organs. However, it is not clear what prompts the T cells to accumulate in the connective tissues of these individuals. Autoimmune diseases develop when the immune system mistakenly identifies host cells as being a threat to the body. Normally, the immune system recognizes healthy body cells by the presence of particular proteins on the surface of the cells. A set of surface proteins called the major histocompatibility complexes (MHCs) play a major role in this process, but there are also many other surface proteins that play more minor roles.
In 2002, researchers developed a method that can trigger the symptoms of systemic scleroderma in mice. This method involves transplanting bone marrow from one mouse into another mouse. Both mice have identical MHC proteins on the surfaces of their cells, but have some differences in other cell surface proteins, and so the bone marrow from the donor mouse triggers an immune response in the recipient.
To better understand how this mouse "model" of systemic scleroderma works, Ogawa, Morikawa et al. refined the method so that they could just transplant specific types of bone marrow cells into the recipient mice. The experiments reveal that bone marrow stromal stem cells, but not so-called "hematopoietic stem cells", from a donor mouse are responsible for triggering the immune response and disease symptoms in the recipients.
Ogawa, Morikawa et al.'s findings show that mismatched minor cell surface proteins on bone marrow stromal stem cells can trigger symptoms of systemic scleroderma in mice. Further studies are required to find out how these cells encourage T cells to trigger an autoimmune response.
Results
Mismatched PaS-BMSCs is a key inducer of fibrosis after bone marrow transplantation A known bone marrow transplantation (BMT) model using 8-week-old donor B10.D2 (H-2d) mice and recipient BALB/c mice (H-2d), is a MHC-compatible, minor histocompatibility antigen (miHA)-incompatible model of systemic fibrosis (Figure 1-figure supplement 1A ) (Zhang et al., 2002) . Signs of fibrosis appear by 3 weeks after BMT and progresses to a full-blown disease by 8 weeks characterized by excessive fibrosis of the lacrimal gland, conjunctiva, salivary gland, skin, lung, liver, and intestine ( Figure 1-figure supplement 1B,C) .
In order to elucidate the source and role of donor-derived fibroblasts, we first modified the SSc model by co-transplanting prospectively isolated HSCs with prospectively isolated BMSCs. PaSBMSCs and side population (SP-HSCs) from B10.D2 or BALB/c were individually isolated ( Figure 1A and Figure 1-figure supplement 2) . We confirmed that PaS BMSCs cells expressed CD29, CD90, and CD106, known as established markers of BMSCs. However, CD31 and CD133, markers of endothelial cells, consisted of only a small portion of the PaS BMSCs fraction (Figure 1 -figure supplement 2C). These PaS-BMSCs and side population (SP-HSCs) from B10.D2 or BALB/c were systemically co-transplanted into BALB/c recipients as defined combinations (Figure 1Bi-iv) . Unlike the original model using WBM, the graft does not include donor type mature hematopoietic and non-hematopoietic cells, and the cells were provided from each lineage of stem cell after bone marrow engraftment.
Notably, progressive fibrosis was only observed in mice receiving mismatched BMSCs ( Figure 1Bii ,iv and Figure 1 -figure supplement 3Aii,iv). The recipients of mismatched HSCs combined with syngeneic BMSCs were indistinguishable from syngeneic HSC and syngeneic BMSC recipients. Physicological connective tissues are also stained in blue in the lacrimal gland, salivary gland, and intestine when BALB/c mice received mismatched HSCs and syngeneic BMSCs (Figure 1Bi ,iii and Figure 1 -figure supplement 3Ai,iii). Since heat-shock protein 47 (HSP47), a molecular chaperon specific to collagen-secreting cells, has been reported as a useful marker for fibroblasts in paraffin-embedded tissue sections (Kuroda and Tajima, 2004) , we determined the state of fibrosis by (1) semi-quantitative analysis to count the number of HSP47+ fibroblasts per field and (2) Mallory staining, a specific marker of connective tissue ( Figure 1B ,C and Figure 1 -figure supplement 3A, B) (Brack et al., 2007) . Fibrotic lesions in mismatched BMSC recipients had significantly higher HSP47 + fibroblasts ( Figure 1C ). Lacrimal gland function was also reduced only in mismatched BMSC recipients ( Figure 1D ). In addition, all these observations were canceled in recipients of BMSCdepleted WBM transplantation ( Figure 1Bv ,Cv,Dv and Figure 1 -figure supplement 3Av,Bv). Minimal Mallory staining areas are physiological changes and necessary to support the structure of ducts and intestinal walls ( Figure 1-figure supplement 4) . The severity of fibrosis triggered by mismatched BMSCs was dose dependent on the number of transplanted BMSCs ( Figure 1E,F) . These results suggest that mismatched donor BMSCs or their progeny triggered the onset of disease. Cells double positive for HSP47 and enhanced green fluorescent protein (EGFP) were detected in fibrotic tissue when mismatched EGFP + B10.D2 PaS-BMSCs were transplanted with wild-type B10.
D2 SP cells ( Figure 2A ). Approximately 42.9 ± 7.3% of the HSP47 + cells in fibrotic tissue were GFP + ,
indicating that the majority of fibroblasts were derived from donor PaS-BMSCs ( Figure 2A ). On the other hand, a notable number of cells derived from mismatched donor EGF + SP-HSCs also migrated to fibrotic lesions, but none of the GFP + cells expressed HSP47 ( Figure 2B ). The lineage exclusivity of this transplantation excludes the possibility that HSP47 + fibroblasts were derived from SP-HSCs as shown in our previous report (Koide et al., 2007) . The accumulation of donor-derived fibroblasts was not observed in syngeneic transplantation, where fibrosis does not occur ( Figure 2C ). HSP47 expression is clearly seen especially in activated fibroblasts (Figure 2A ), but very faint expression is detected in quiescent fibroblasts in the syngeneic BMSCs transplanted recipients' target organs ( Figure 2C ). These results suggest that mismatched BMSCs migrate into the target organs and proliferate under pathological microenvironment. In vitro culture also confirmed that the majority of fibroblasts from lacrimal gland cultures were derived from mismatched EGFP + BMSC ( Figure 2D , right), whereas no EGFP + fibroblasts were observed after mismatched EGFP + HSC transplantation ( Figure 2D , left). This suggests that the migration of donor-derived fibroblasts to peripheral organs is one of the characteristic phenomena associated with pathogenesis or progression of this disease.
Host T cells are required for the progression of fibrosis
The progression of fibrosis in this mouse model is T-cell-dependent as evidenced by the fact that fibrosis was not observed when BALB/c-nu/nu mice were used as recipients of mismatched B10.D2 BMSCs transplantation (Figure 2-figure supplement 1 ). The next question was whether these pathogenic T cells were donor-derived T cells, or residual host T cells that lost self-tolerance. Both host-derived T cells and donor HSC-derived T cells are believed to exist in this mouse model, because mature T cells often escape radiation damage and remain in the peripheral blood of recipients . Interestingly, almost all spleen cells were donor-derived in matched WBMT, whereas the remaining host-derived cells after mismatched WBMT were higher in mismatched WBMT ( Figure 2E ).
To determine the origin of T cells, we used BALB/c-RAG2KO mice as recipients or donors of HSCs. In the former lacking recipient T cells ( Figure 3A) , the fibrosis was not observed ( Figure 3A ( Figure 5C , Right). We conducted IL-17 ELISA using the serum samples from the same mice of the experiments shown in Figure 4C . IL-17 concentration significantly increased in the serum from the adoptive transferred recipients group compared with the control group ( Figure 5D ). These results strongly suggest that recipient mature T cells act as an effector for mismatched PaS-BMSCs during the onset of fibrosis. Since EGFP + BMSC-derived cells were not observed in the cortical region of the thymus within this time frame (data not shown), it is unlikely that escape of donor-derived T cells from negative selection by the host thymus is involved in the recognition of host tissue as non-self. Figure 6A,B) . Interestingly, T cells also responded to matched (BALB/c) BMSCs ( Figure 6A,B) , suggesting that recipient T cells acquired the auto-reactive nature via antigen spreading (Shlomchik, 2007) . In addition, either strainderived BMSCs induced slight IL-6 secretion when reacted with naive T cells from wild-type mice ( Figure 6B ). Both PaS-BMSCs and T cells from mismatched BMSC-transplanted recipients produce IL-6 ( Figure 6C ).
Since the reaction was significantly suppressed by anti-MHC-class II antibody ( Figure 6D ) and CD4 + T cells were predominant over CD8 + T cells ( Figure 6E ), it was suggested that PaS-BMSCs themselves act as antigen-presenting cells via MHC-class II. Flowcytometry also revealed that MHCclass II molecule was expressed in only a rare subset of PaS cells, but the frequency of MHC-class II expressing cells was significantly increased after co-culture with recipient T cells ( Figure 6F ). These data suggest that mismatched BMSCs and host T cells stimulate each other via unknown but specific antigens expressed in mismatched BMSCs, but not in DCs, presented by MHC class II molecules.
Temporal increase of regulatory T-cells is abrogated with mismatched BMSC
We further examined the in vivodynamics of T cells and BMSCs. We found that serum levels of IL-6 increased in recipient mice transplanted with mismatched BMSCs starting at 3 weeks after transplantation ( Figure 7A ). This coincided with the appearance of PaS-BMSC-derived cells in the peripheral blood of recipients starting at 3 weeks after transplantation and gradually increasing up to 7 weeks ( Figure 7B ). Interestingly, significant number of the PaS-BMSC-derived cells in the peripheral blood expressed MHC class II antigens, whereas the vast majority of them were negative prior to transplantation ( Figure 6F,7B) . Increased IL-6 during an autoimmune process leads to the induction of Th17 cells and a decrease in regulatory T cells (Tregs) (Bettelli et al., 2006) . We found that CD4 + CD25 + Foxp3 + Tregs in peripheral blood transiently increased following lethal irradiation after syngeneic transplantation of BMSCs or WBM, which recovered to basal levels by 8 weeks. This transient increase in Tregs, reaching statistical significance at 3 weeks, was not observed after mismatched BMSC or WBM transplantation ( Figure 7C ,D). This was followed by an increase of Th17 cells in both the mismatched WBMT and BMSC groups reaching statistical significance compared to syngeneic controls at 3 weeks in the WBMT group, and 8 weeks in the BMSC mismatched group. Mismatched BMT more rapidly induces the appearance of CD4 + /Th17 + cells compared with mismatched PaS cells. (Figure 7E,F) . These results suggest that the interaction of mismatched BMSCs and recipient T cells induce IL-6 production and lead to pathological changes in major organs similar to autoimmune disease, with inflammation due to Th17 cells via suppression of transient increase in Tregs.
Discussion
We have reported the role of donor BMSCs in the pathogenesis of fibrosis associated with autoimmune SSc in a MHC-matched, minor antigen mismatched mouse model. Our data show that depletion of BMSCs from donor whole bone marrow significantly reduced fibrosis in all organs examined, and rescued mice from lacrimal gland dysfunction associated with the disease. These findings suggest the possible role of donor BMSCs in the initiation of the autoimmune process, as the number of BMSCs in graft correlated with severity of fibrosis ( Figure 1E,F) . Furthermore, the onset of true autoimmune disease in these mice was shown by the repression of Treg induction, followed by an increase in Th17 effector cells of host origin. This shows that migrating donor PaS-BMSCs are the initial trigger of events leading to increased levels of circulating IL-6, followed by a decrease in Tregs, and conversely an increase in host-derived Th17 cells. Activation or maturation of BMSC-derived The following source data is available for figure 6:
Source data 1. T cell proliferation after co-culturing of donor or recipient BMSCs and splenic dendritic cells (DC Figure 6A and Figure 6B . Although the auto-antigen responsible for the autoimmune type reaction still needs to be identified, a common antigen specifically expressed in BMSCs of B10.D2 and BALB/c with different isoforms or SNIPs, is one of the most probable candidates. Since naive T cells responded to PaSBMSCs in vitro at low levels, we speculate that auto-reactive T cells that are only present in basal levels under normal conditions (Sakaguchi et al., 2008) can recognize minor differences between B10. D2 and BALB/c BMSCs. The lack of fibrosis following mismatched HSC transplantation suggests that hematopoietic lineage cells, including DCs, did not express such a molecule. The identical phenotype was observed when host and recipient were reversed (i.e. BALB/c BMSCs transplanted to B10. D2 recipients, data not shown). This implies that both B10.D2 and BALB/c BMSCs can be a primary inducer against mismatched recipient T cells, showing that the autoimmune-related fibrosis in this model was due to difference in strain, and not a specific reaction of B10.D2 BMSCs and BALB/c T cells.
The novelty of our study is the use of prospectively isolated BMSCs combined with prospectively isolated HSCs. Previous studies have used culture-isolated BMSCs, which do not reflect the physiological role of these cells in vivo. Functional differences between in vitro and in vivo observations may explain discrepancies in the anti-inflammatory and pro-inflammatory effects of BMSCs reported in the literature (See review by Bernardo et. al. (Bernardo and Fibbe, 2013) . Our study has also demonstrated that donor BMSCs can contribute to the fibroblast population observed in fibrotic lesions of the host. Our findings suggest that once mismatched BMSCs migrate into the target organs via certain homing signals, mismatched BMSCs encounter T cells and proliferate and activate under the pathological microenvironment (Figure 2A ). This phenomenon may not be present in syngeneic BMSCs transplantation where an allogeneic response does not occur. As for HSP47 expression, it is clearly seen in activated fibroblasts, but only very faint expression is detected in quiescent fibroblasts in the syngeneic BMSC-transplanted recipients' target organs. Interestingly, a fraction of BMSCs mobilized in the peripheral blood expressed MHC class II molecules ( Figure 6B ). Preliminary data show that these cells also express CD45 and type I collagen (data not shown), which corresponds with the phenotype of fibrocytes reported in the literature (Abe et al., 2001; Chesney et al., 1997; Mielcarek et al., 2003; Phillips et al., 2004; Wang et al., 2007; Yang et al., 2002) . Further studies are required to elucidate the association of PaS-BMSCs and fibrocytes.
Interestingly, this SSc mouse model has also been used as a model of chronic graft-versus-host disease (cGVHD) (Kaplan et al., 2004; Kim et al., 2007) . The phenotype of cGVHD characterized by systemic fibrosis and severe dry eye is very similar to this SSc mouse phenotype. Unlike conventional cGVHD that is believed to be caused by donor T cells, our results show that radio-resistant residual recipient T cells, but not donor-HSC derived de novo T cells, were activated following mismatched BMSC transplantation. Although we do not believe that our findings in this mouse model could be The following source data is available for figure 7:
Source data 1. Serum IL-6 concentration after mismatched BMSC transplantation compared to syngeneic BMSC transplantation. directly applied to human cGVHD cases, it is worth noting this phenomenon. In fact, several previous reports have shown that residual recipient CD4 + T cells regulate cGVHD Blazar et al., 2000; Jaffee and Claman, 1983) . In addition, cGVHD has occurred in a surprisingly high fraction of nonmyeloablative stem cell transplant recipients Mielcarek et al., 2003; Schetelig et al., 2002) (Mabuchi et al., 2013) . In addition, recent reports showed that the incidence of cGVHD was less following cord blood transplantation (CBT) compared to peripheral blood stem-cell transplantation (PBSCT) (Takahashi et al., 2007; Uchino et al., 2012) . We have found that BMSCs are rarely detected in cord blood but are abundant in G-CSF-mobilized PBL (Mabuchi et al., 2013) , which may indicate that the onset of cGVHD may correlate with the number of BMSCs transplanted. Taken all, the reduced risk of cGVHD may have been due to the removal or absence of donor BMSCs as we showed in our BMSC-depleted model. Further studies are required for monitoring the frequency of donor BMSCs in grafts and residual host T cells in human cGVHD patients to elucidate the possible role of donor BMSCs in the pathogenesis. In summary, prospective transplantation of freshly purified BMSCs and HSCs into BALB/c-RAG2KO suggests that transplantation of minor antigen-mismatched MHC-compatible BMSCs interact with residual host T cells to induce the autoimmune phenotype observed in fibrosis associated with the SSc mouse model. While the responsible antigen remains to be elucidated, our data suggest that accidental recognition of self-minor antigens on MHC class II + BMSCs may be involved in systemic fibrosis observed in autoimmune disease.
Materials and methods

Mice
B10.D2, BALB/c, and BALB/c background Nude mice 8-10 week of age were purchased from Sankyo Laboratory, Inc. (Tokyo, Japan). B10.D2 GFP mice were obtained by backcrossing of B10.D2 mice with C57BL/6 GFP mice (Japan SLC Ltd). The 10th generation of backcrossed B10.D2 GFP progenies was used for experiments. RAG2KO on BALB/c background were kindly provided from Dr. Shigeo Koyasu (Keio University). All experimental procedures and protocols were approved by the ethics committee of Keio University and were in accordance with the Guide for the Care and Use of Laboratory Animals (# 09152). We followed the ARRIVE guidelines for reporting in vivo experiments in animal research (Kilkenny et al., 2010) .
Isolation of SP-HSCs
Bone marrow cells, suspended at 1x10 6 cells/ml in calcium-and magnesium-free Hanks balanced salt solution (HBSS) supplemented with 2% fetal calf serum, 10 mM HEPES, and 1% penicillin/streptomycin (HBSS+) were incubated with 5 mg/ml Hoechst 33342 (Sigma Aldrich, St. Louis, MO) for 60 min at 37˚C. The side population (SP) was sorted as described previously (Matsuzaki et al., 2004) . (Figure 1-figure supplement 2) Isolation of CD45 -TER119 -PDGFRa + Sca-1 + cells (BMSCs)
Purified BMSCs were isolated by flowcytometry as described previously (Morikawa et al., 2009a; 2009b) . Briefly, femurs and tibias were dissected and crushed with a pestle. The bone marrow was gently washed in HBSS+. Collagenase (0.2%) was used to digest the minced tibia and femur in DMEM without fetal bovine serum at 37˚C for 1 hr. After red blood cell lysis, the residual cells were stained with FITC-labeled anti-Sca-1 (Ly6A/E), APC-labeled anti-PDGFR-a (APA-5), PE-labeled anti-CD45 (30-F-11), and PE-labeled anti-TER119 (TER-119) (all from e-Bioscience, San Diego, CA). Analysis and sorting were performed on a triple-laser MoFlo flow cytometer (Beckman Coulter, Brea, CA). CD45 -TER119 -PDGFRa + Sca-1 + cells were routinely prepared at 99% purity by this method (Figure 1-figure supplement 2) (Morikawa et al., 2009a were used. FITC-labeled rat anti-mouse IgG2a, k for Sca-1(e-Bioscience) was used. were intravenously injected into the tail vein (200 ml/ per mouse) of recipient mice that had been lethally irradiated with a dose of 7.0 Gy as indicated in our previous studies (Matsuzaki et al., 2004; Morikawa et al., 2009a) . This is approximately equivalent to 50 CFU-F in 1x10 4 PDGFRa + /Sca1 + cells (Morikawa et al., 2009a; 2009b) while approximately 10 to 50 HSCs are found in 1000 SP KSL cells (Okada et al., 1992) . Therefore, while the ratio of PaS-BMSC to SP KSL was 10:1 in the donor, the actual number of BMSCs to HSCs was approximately 1:1 (Okada et al., 1992) .
BMSCs and HSCs co-transplantation
T-cell isolation for co-culture with BMSCs
Spleens were obtained from mice that received B10.D2 BMSC or BALB/c BMSC transplants. T cells and DCs were purified from the spleens by anti-CD90.2 monoclonal antibody (mAb)-conjugated microbeads or anti-CD11c mAb-conjugated microbeads (Miltenyi Biotic, Bergisch Gladbach, Germany), respectively, according to the manufacturer's instructions. The purity was consistently > 98%. T cells were cultured alone or co-cultured with PaS-BMSCs at a ratio of 10:1 (T cells: BMSCs).
Adoptive transfer of splenic T cells from mismatched BMSC transplanted recipients.
Adoptive transfer was performed in accordance with previous publication (Arakaki et al., 2003; Niederkorn et al., 2006) . Briefly, splenic T cells were isolated from mismatched PaS-BMSC transplanted BALB/c recipients as described above, and 3x10 6 cells were transferred into BALB/c background nude mice without any pre-treatment. The animals were sacrificed 45 days after transfer. Analyses of tissue samples from target organs were performed as shown in the section 'Immunohistochemistry and immunofluorescence'. Splenic cells were collected and prepared for flowcytometry and stained with CD4and IL-17 antibody as shown in the section 'Flowcytometry analysis for IL-17'.
Proliferation assay
Purified B10.D2 PaS-BMSCs and BALB/c PaS-BMSCs were plated at 1x10 4 cells/ well into 96-well plates in triplicate, which were irradiated at 52 Gy after adherence. 1x10 5 purified mouse T cells were added to each well. On the fourth day, 5-bromo-2'-deoxyuridine (BrdU) was added. Twentyfour hours later, BrdU uptake was quantified by cell proliferation enzyme-linked immunosorbent assay (ELISA) using a BrdU Kit (Roche Applied Science, Penzberg, Germany) (Guo et al., 2009) . In some experiments, purified B10.D2 PaS-BMSCs were co-cultured with T cells isolated from mismatched PaS-BMSC-transplanted recipient mice. Cells were treated with either blocking anti-MHC class II antibody (M5/114.15.2, Biolegend) or isotype control. The supernatant of the co-cultures was subjected to IL-6 ELISA using commercial kit (BD Biosciences).
For Foxp3 staining, whole blood samples were co-stained with anti-CD4-FITC and anti-CD25-PE (PC61.5). After fixation and permealization, cells were stained with APC-labeled anti-Foxp3 mAb (FJK-16s) (all mAbs were from e-Bioscience) as described (Chen et al., 2007) . For IL-6, and IL-17 staining, 2 x 10 6 spleen cells were stimulated with 10 ng/ml phorbol myristate acetate (PMA) (Sigma) and 10 ng/ml ionomycin (Sigma) in the presence of the Golgi inhibitor Brefeldin (Sigma) (10 mg/ml) for 4 hr. The cells were then stained with FITC-labeled anti-CD4 (GK 1.5, e-Bioscience) and PElabeled anti-IL-6 (MP5-20F3, BD Pharmingen) or APC-labeled anti-IL-17 (eBio17B7, e-Bioscience) as described (Kappel et al., 2009 
Supplemental methods Whole bone-marrow transplantation
In a typical WBM transplantation, we used 7-to 8-week-old male B10.D2 (H-2d) and female BALB/c (H-2d) mice as donors and recipients, respectively. Briefly, 1x10 6 whole bone marrow cells and 2x10 6 spleen cells (200 ml total) were intravenously injected into the tail vein of recipient mice that had been lethally irradiated with a dose of 7.0 Gy, as indicated in a previous study (Zhang et al., 2002) . Three to five animals per group were studied 3 and 8 weeks after transplantation for each experiment.
Immunohistochemistry and immunofluorescence
Animals were anesthetized using anesthetics by intraperitoneal injection of 5 mg/ml sodium pentobarbital (Sumitomo Dainippon Pharma Co., Ltd, Osaka, Japan) and fixated by perfusion with 4% paraformaldehyde (PFA) at 3 and 8 weeks after transplantation. For histologic examinations, the lacrimal gland, eye, salivary gland, lung, skin, intestine, liver, and thymus were excised, fixed in 4% PFA overnight, embedded in paraffin wax, and processed for hematoxylin-eosin and Mallory staining. Tissue sections of target organs subjected to Mallory staining were assessed for morphometric analysis. A minimum of five randomly selected fields were captured at 200X magnification for each section using a Nikon Coolsope II (Nikon). The fibrotic areas was quantified as the ratio of the blue-stained area to the total stained area (Brack et al., 2007) .
Immunohistochemistry was performed on formalin-fixed paraffin-embedded or frozen tissue sections. The staining patterns were graded semi quantitatively according to the intensity and distribution of the labeling, as described previously (Ogawa et al., 2009) . For immunofluorescent staining for HSP47, a collagen-specific molecular chaperon (SPA-470, Stress Gen Biotechnologies Corp), antigen unmasking was done for paraffin-embedded sections by autoclaving at 120˚C for 20 min or incubating the sections at 37˚C in antigen retrieval solution (Histo VT One, Nacalai Tesque) for 10 min for formalin fixed-frozen sections. For frozen sections, the sections were then blocked with 10% goat serum for 30 min and incubated overnight at 4˚C with an anti-PE labeled rat anti-mouse IL-6 antibody and APC labeled anti-mouse IL-17 antibody. HSP47 antibody cross-reacts with the mouse HSP47 antigen. After washing with PBS, the sections were incubated with an Alexa 488-conjugated goat anti-mouse secondary antibody (Molecular Probes) and the nuclei were stained simultaneously with DAPI. Isotype matched mouse antibodies including mouse Ig G 2b, k antibody for HSP47, rat Ig G1 antibody for IL-6 and rat IgG2a,k antibody for 1L-17 were prepared for negative control. Tissue sections for fluorescent staining were examined with an LSM 700 confocal microscope (Carl Zeiss, Jena, Germany). To assess the histological architecture and staining, all the acquired images were reviewed twice each by two independent observers who were blinded to the source of the samples. The number of HSP47 + fibroblasts/field (at x630 magnification) was counted in at least five different fields on three to five sections. HSP47 + spindle-shaped cells with an oval nucleus that resided in the interstitium were regarded as fibroblasts (Ogawa et al., 2005) .
Serum cytokine analysis
Serum was collected from mice using retro-orbital beads . The concentration of IL-6 and IL-17 in the supernatants was determined by ELISA using a specific kit, according to the manufacturer's instructions (BD Biosciences for IL-6, and R&D systems for IL-17). The experiments were performed in triplicate.
Tear secretion volume measurements
Fibrosis-induced and control mice were anesthetized by intra-peritoneal injection of 5 mg/ml sodium pentobarbital (Sumitomo Dainippon Pharma). Tear secretion was evaluated as described Inaba et al., 2014) . Animals were stimulated 3 min after anesthesia by intra-peritoneal injection of 0.02% pilocarpine solution (1 mg/kg; Santen Pharmaceutical Co., LTD), and tears were collected from the conjunctival sac of the lateral canthus for 15 min using 0.5-ml diameter capillary microglass tubes (Microcaps, Drummond Scientific Company, Broomall, PA). The total tear volume was determined as the average of three separate measurements of 5 min each.
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